Malignant Mesothelioma — Trials

Malignant Mesothelioma — Trials · CancerIndex

Clinical trials

Registered studies

478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 55
Ph III recruiting: 1
Growth YoY: —
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.4%
Trials / 1,000 deaths: 45.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (81)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03656549	Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I)	completed	Phase 4	6	Radboud University Medical CenterOTHER	1	Dec 17, 2024	clinicaltrials
NCT06010277	Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX)	unknown	Phase 4	50	Amphia HospitalOTHER	1	Aug 24, 2023	clinicaltrials